Captor Therapeutics S.A.
ISIN: PLCPTRT00014 | Ticker: CTX | LEI: 259400JHH1S2I2S4O735
Country: Poland
Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".
Captor Therapeutics is a Swiss-Polish company. Captor GmbH entity operates in Basel, the pharma hub of Switzerland, providing excellent opportunities for business development, while our state-of-the-art laboratories are located in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.
2015
Served areaWorldwide
HeadquartersDuńska 11, 54-427 Wrocław – Poland
| Line item in (pln) | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 143,541,000.00 | N/A | 113,000,000.00 |
| Noncurrent Assets | N/A | 12,986,000.00 | N/A | 11,676,000.00 |
| Property Plant And Equipment | N/A | 12,612,000.00 | N/A | 10,666,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 180,000.00 | N/A | 602,000.00 |
| Intangible Assets Under Development | N/A | 180,000.00 | N/A | 180,000.00 |
| Other Noncurrent Receivables | N/A | 14,000.00 | N/A | 228,000.00 |
| Current Assets | N/A | 130,555,000.00 | N/A | 101,324,000.00 |
| Trade And Other Current Receivables | N/A | 11,706,000.00 | N/A | 9,678,000.00 |
| Other Current Financial Assets | N/A | 0.00 | N/A | 19,854,000.00 |
| Other Current Nonfinancial Assets | N/A | 906,000.00 | N/A | 756,000.00 |
| Cash and cash equivalents | 10,654,000.00 | 117,943,000.00 | 117,943,000.00 | 71,036,000.00 |
| Equity And Liabilities | N/A | 143,541,000.00 | N/A | 113,000,000.00 |
| Equity | -1,004,000.00 | 124,201,000.00 | 124,201,000.00 | 96,322,000.00 |
| Issued Capital | N/A | 413,000.00 | N/A | 417,000.00 |
| Retained Earnings | N/A | -58,208,000.00 | N/A | -94,102,000.00 |
| Share Premium | N/A | 170,031,000.00 | N/A | 170,031,000.00 |
| Other Reserves | N/A | 175,000.00 | N/A | 175,000.00 |
| Reserve Of Sharebased Payments | N/A | 11,779,000.00 | N/A | 19,785,000.00 |
| Liabilities | N/A | 19,340,000.00 | N/A | 16,678,000.00 |
| Noncurrent Liabilities | N/A | 2,973,000.00 | N/A | 3,286,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 33,000.00 | N/A | 51,000.00 |
| Current Liabilities | N/A | 16,367,000.00 | N/A | 13,392,000.00 |
| Other Shortterm Provisions | N/A | 6,262,000.00 | N/A | 1,733,000.00 |
| Trade And Other Current Payables | N/A | 4,738,000.00 | N/A | 7,816,000.00 |
| Current Deferred Income Other Than Current Contract Liabilities | N/A | 126,000.00 | N/A | 126,000.00 |
| Line item in (pln) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 3,986,000.00 | 9,158,000.00 |
| Other Income | 2,694,000.00 | 2,269,000.00 |
| Profit Loss From Operating Activities | -31,709,000.00 | -38,364,000.00 |
| Finance Income | 0.00 | 3,127,000.00 |
| Finance Costs | 863,000.00 | 657,000.00 |
| Profit Loss Before Tax | -32,572,000.00 | -35,894,000.00 |
| Profit Loss From Continuing Operations | -32,572,000.00 | -35,894,000.00 |
| Profit (loss) | -32,572,000.00 | -35,894,000.00 |
| Profit Loss Attributable To Owners Of Parent | -32,572,000.00 | -35,894,000.00 |
| Line item in (pln) | 01.01.2022 | 02.01.2021 | 01.01.2023 | 02.01.2022 |
|---|---|---|---|---|
| Profit (loss) | -32,572,000.00 | N/A | -35,894,000.00 | N/A |
| Adjustments For Reconcile Profit Loss | 4,099,000.00 | N/A | 12,946,000.00 | N/A |
| Adjustments For Decrease Increase In Other Operating Receivables | -68,000.00 | N/A | 150,000.00 | N/A |
| Adjustments For Depreciation And Amortisation Expense | 7,355,000.00 | N/A | 7,094,000.00 | N/A |
| Adjustments For Provisions | 5,536,000.00 | N/A | -4,512,000.00 | N/A |
| Adjustments For Unrealised Foreign Exchange Losses Gains | 36,000.00 | N/A | -111,000.00 | N/A |
| Adjustments For Sharebased Payments | 9,495,000.00 | N/A | 8,006,000.00 | N/A |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | 409,000.00 | N/A | -2,574,000.00 | N/A |
| Adjustments For Reconcile Profit Loss | 4,099,000.00 | N/A | 12,946,000.00 | N/A |
| Cash Flows From Used In Operating Activities | -28,473,000.00 | N/A | -22,948,000.00 | N/A |
| Other Cash Receipts From Sales Of Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | 0.00 | N/A | 33,872,000.00 | N/A |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | 0.00 | N/A | 53,539,000.00 | N/A |
| Interest Received Classified As Investing Activities | 0.00 | N/A | 2,929,000.00 | N/A |
| Cash Flows From Used In Investing Activities | -5,113,000.00 | N/A | -17,630,000.00 | N/A |
| Proceeds From Issuing Shares | 148,240,000.00 | N/A | 4,000.00 | N/A |
| Repayments Of Borrowings Classified As Financing Activities | 209,000.00 | N/A | 0.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | 6,747,000.00 | N/A | 5,758,000.00 | N/A |
| Interest Paid Classified As Financing Activities | 409,000.00 | N/A | 575,000.00 | N/A |
| Cash Flows From Used In Financing Activities | 140,875,000.00 | N/A | -6,329,000.00 | N/A |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 107,289,000.00 | N/A | -46,907,000.00 | N/A |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | 107,289,000.00 | N/A | -46,907,000.00 | N/A |
| Cash and cash equivalents | 117,943,000.00 | 10,654,000.00 | 71,036,000.00 | 117,943,000.00 |
Please note that some sums might not add up.
PLCPTRT00014
LEI259400JHH1S2I2S4O735
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.